Two years post-merger, Flagship’s Senda refines pipeline and replenishes the bank

Kyle LaHucik

Associate Editor

Senda Biosciences will look a little different than it did two years ago when Flagship Pioneering unwrapped the bow on the venture, a merger of Senda and Kintai Therapeutics.

Originally home to six preclinical programs with ambitions for treating multiple sclerosis, Parkinson’s, colorectal cancer, chronic kidney disease, obesity and other diseases, the startup is fine-tuning its path and will soon present a clearer scope of its future.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Two years post-merger, Flagship’s Senda refines pipeline and replenishes the bank

Kyle LaHucik

Associate Editor

To read Endpoints News become a free subscriber

AstraZeneca fleshes out pivotal data on $930M rare blood disorder drug it wants to pair with Soliris, Ultomiris

FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

AstraZeneca enlists UK Treg biotech for type 1 diabetes, inflammatory bowel disease deal featuring $85M upfront

Editas gives first look at CRISPR data in sickle cell, beta thalassemia six months after layoffs, refocus

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape

Two years post-merg­er, Flag­ship’s Sen­da re­fines pipeline and re­plen­ish­es the bank

Kyle LaHucik

Associate Editor

To read Endpoints News become a free subscriber

As­traZeneca flesh­es out piv­otal da­ta on $930M rare blood dis­or­der drug it wants to pair with Soliris, Ul­tomiris

FDA sets De­cem­ber ap­proval de­ci­sion for first CRISPR ther­a­py, with 94% of pa­tients free of sick­le cell crises

Who pays the most (and least) in bio­phar­ma? We crunched me­di­an salary da­ta from 175 com­pa­nies

As­traZeneca en­lists UK Treg biotech for type 1 di­a­betes, in­flam­ma­to­ry bow­el dis­ease deal fea­tur­ing $85M up­front

Ed­i­tas gives first look at CRISPR da­ta in sick­le cell, be­ta tha­lassemia six months af­ter lay­offs, re­fo­cus

The new rules of can­cer care: Re­spond­ing to in­creas­ing CMS in­flu­ence on the on­col­o­gy land­scape

Two years post-merger, Flagship’s Senda refines pipeline and replenishes the bank

AstraZeneca fleshes out pivotal data on $930M rare blood disorder drug it wants to pair with Soliris, Ultomiris

FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

AstraZeneca enlists UK Treg biotech for type 1 diabetes, inflammatory bowel disease deal featuring $85M upfront

Editas gives first look at CRISPR data in sickle cell, beta thalassemia six months after layoffs, refocus

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape